Researchers developed an AI model to detect myocardial ischemia and coronary microvascular and vasomotor dysfunction using ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...

CRYSTAL LAKE, Ill. - Aptar Group, Inc. (NYSE:ATR) announced that its Bidose Liquid Nasal Spray System will be used to deliver CARDAMYST (etripamil), a treatment recently approved by the U.S. Food and ...

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the ...

Intranasal etripamil is the first self-administered, on-demand therapy for PSVT, allowing treatment outside healthcare settings. The RAPID trial showed 64% of etripamil-treated patients returned to ...

Milestone Pharmaceuticals Inc. received FDA approval for CARDAMYST, a nasal spray for acute PSVT episodes, but faces a challenging commercialization path. The PSVT market is crowded with effective, ...

Greetings. Welcome to Milestone Pharmaceuticals CARDAMYST FDA Approval Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Michael Wood ...

The approval marks Cardamyst as the first FDA-approved treatment in over 30 years for more than 2 million Americans with PSVT. Cardamyst nasal spray is a novel and rapid-acting calcium channel blocker ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given Milestone Pharmaceuticals its first FDA approval in its 22-year history. The ...

Investing.com -- Milestone Pharmaceuticals (NASDAQ:MIST) stock surged 35% after the company received FDA approval for CARDAMYST, the first self-administered nasal spray for adults with paroxysmal ...